Novel function of STAT1β in B cells: induction of cell death by a mechanism different from that of STAT1α

被引:17
|
作者
Najjar, Imen [1 ]
Schischmanoff, Pierre Olivier [1 ]
Baran-Marszak, Fanny [1 ]
Deglesne, Pierre-Antoine [1 ]
Youlyouz-Marfak, Ibtissam [3 ,4 ,5 ]
Pampin, Mathieu [2 ]
Feuillard, Jean [3 ,4 ,5 ]
Bornkamm, Georg W. [6 ]
Chelbi-Alix, Mounira K. [2 ]
Fagard, Remi [1 ]
机构
[1] Univ Paris 13, Hop Avicenne, AP HP, Serv Biochim,EA 3406, F-93009 Bobigny, France
[2] Inst Lwoff, CNRS, FRE 2937, Villejuif, France
[3] CHU Dupuytren, CNRS, UMR 6101, Limoges, France
[4] CHU Dupuytren, Hematol Lab, Limoges, France
[5] Univ Limoges, Fac Med, F-87065 Limoges, France
[6] GSF Forschungszentrum Umwelt & Gesundheit, Inst Clin Mol Biol & Tumor Genet, Munich, Germany
关键词
B lymphocytes; p53; fludarabine;
D O I
10.1189/jlb.0508287
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Alternate splicing of STAT1 produces two isoforms: alpha, known as the active form, and beta, previously shown to act as a dominant-negative factor. Most studies have dealt with STAT1 alpha, showing its involvement in cell growth control and cell death. To examine the specific function of either isoform in cell death, a naturally STAT1-deficient human B cell line was transfected to express STAT1 alpha or STAT1 beta. STAT1 alpha, expressed alone, enhanced cell death, potentiated the fludarabine-induced apoptosis, and enhanced the nuclear location, the phosphorylation, and the transcriptional activity of p53. Unexpectedly, STAT1 alpha, expressed alone, induced cell death through a mechanism that was independent of the nuclear function of p53. Indeed, in STAT1 beta-expressing B cells, p53 was stricktly cytoplasmic where it formed clusters, and there was no induction of the transcriptional activity of p53. These data reveal a novel role of STAT1 beta in programmed cell death, which is independent of p53. J. Leukoc. Biol. 84: 1604-1612; 2008.
引用
收藏
页码:1604 / 1612
页数:9
相关论文
共 50 条
  • [21] Stat1 and phosphorylated Stat1 are increased in lymphocytes and monocytes of patients with systemic lupus erythematosus
    M Aringer
    T Karonitsch
    CW Steiner
    E Feierl
    G Steiner
    JS Smolen
    Arthritis Research & Therapy, 7
  • [22] Interferon-γ inhibits interferon-α signalling in hepatic cells:: evidence for the involvement of STAT1 induction and hyperexpression of STAT1 in chronic hepatitis C
    Radaeva, S
    Jaruga, B
    Kim, WH
    Heller, T
    Liang, TJ
    Gao, B
    BIOCHEMICAL JOURNAL, 2004, 379 : 199 - 208
  • [23] NOVEL GAIN OF FUNCTION MUTATION IN STAT1 ASSOCIATED WITH DISSEMINATED ZYGOMYCOSIS
    Hanks, Mary E.
    Kumar, Nilay
    Davis, Brian C.
    Van Wagoner, Nicholas
    Hsu, Amy P.
    Merlin, Jessica S.
    La Hoz, Ricardo
    Chandrasekaran, Prabha
    Zerbe, Christa S.
    Holland, Steven M.
    Sampaio, Elizabeth P.
    JOURNAL OF CLINICAL IMMUNOLOGY, 2013, 33 (03) : 681 - 681
  • [24] Novel STAT1 gain-of-function mutation and suppurative infections
    Giardino, Giuliana
    Somma, Domenico
    Cirillo, Emilia
    Ruggiero, Giuseppina
    Terrazzano, Giuseppe
    Rubino, Valentina
    Ursini, Matilde Valeria
    Vairo, Donatella
    Badolato, Raffaele
    Carsetti, Rita
    Leonardi, Antonio
    Puel, Anne
    Pignata, Claudio
    PEDIATRIC ALLERGY AND IMMUNOLOGY, 2016, 27 (02) : 220 - 223
  • [25] 转录因子STAT1两个亚型STAT1α和STAT1β高表达载体的构建及鉴定
    李靖
    伊静
    蓝茜
    李玥
    刘莉
    梁栋
    杜小娟
    武丽涛
    闫小飞
    杨旭东
    张富军
    吕社民
    李冬民
    国外医学(医学地理分册), 2016, 37 (01) : 49 - 53
  • [26] Interferon-γ inhibits interferon-α signalling in hepatic cells: Evidence for the involvement of STAT1 induction and hyperexpresslon of STAT1 in chronic hepatitis C
    Radaeva, Svetlana
    Jaruga, Barbara
    Kim, Won-Ho
    Heller, Theo
    Liang, T. Jake
    Gao, Bin
    Biochem. J., 1600, 1 (199-208):
  • [27] STAT1 gain-of-function and chronic demodicosis
    Molho-Pessach, Vered
    Meltser, Arnon
    Kamshov, Adaia
    Ramot, Yuval
    Zlotogorski, Abraham
    PEDIATRIC DERMATOLOGY, 2020, 37 (01) : 153 - 155
  • [28] RUXOLITINIB EFFECTS ON STAT1 GAIN OF FUNCTION MUTATIONS
    Zimmerman, Ofer
    Rosen, Lindsey B.
    Hsu, Amy P.
    Sampaio, Elizabeth P.
    Rosenzweig, Sergio D.
    Zerbe, Christa S.
    Holland, Steven M.
    JOURNAL OF CLINICAL IMMUNOLOGY, 2015, 35 (03) : 327 - 327
  • [29] Is Gain-of-function STAT1 CMC An Interferonopathy?
    Al Shehri, Tariq
    Abinun, Mario
    Gennery, Andrew R.
    Rice, Gillian I.
    Crow, Yanik J.
    Lilic, Desa
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2015, 182 : 15 - 15
  • [30] STAT1/STAT3 Gain of Function and Mechanisms of Immune Dysregulation
    Kiykim, Ayca
    TURKISH JOURNAL OF IMMUNOLOGY, 2024, 12 : 47 - 52